Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05088395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

Study acronym: ALCINA4
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study arms: 10 to 12v13
  2. Re-verified, no change to tracked fieldsv12
  3. Enrollment target: 1000 to 2050
    • Eligibility criteria expanded, about 10 words
    • Study arms: 9 to 10
    v11
  4. Primary and study completion dates: Jun 1, 2028 to Jun 1, 2031
    • Study arms: 7 to 9
    v10
  5. Study completion date: Jun 1, 2029 to Jun 1, 2028
    • Start date: May 27, 2022 to May 19, 2022
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria expanded, about 8 words
    • Site contacts updated at 1 of 2 sites
    v8
  2. Primary completion date: Nov 30, 2027 to Jun 1, 2028
    • Enrollment target: 820 to 1000
    • Study completion date: Nov 30, 2027 to Jun 1, 2029
    • Study arms: 6 to 7
    v7
  3. Site details revised at 1 of 2 sites
    • Study arms: 4 to 6
    v6
  4. Primary endpoints: 13 to 15
    • Primary and study completion dates: Jan 30, 2028 to Nov 30, 2027
    • Study arms: 3 to 4
    v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 30, 2022 to May 27, 2022
    • Site details revised at 2 of 2 sites
    v4
  6. Primary completion date: Nov 1, 2025 to Jan 30, 2028v3 Show 5 more changesShow less
    • Start date: Nov 1, 2021 to Jan 30, 2022
    • Primary endpoints: 9 to 13
    • Study completion date: Mar 1, 2027 to Jan 30, 2028
    • Eligibility criteria shortened, about 10 words
    • Study arms: 2 to 3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort. Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.
Trial Details
NCT Number NCT05088395
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Cancer
Related terms Neoplasms
Enrollment 2,050 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov